Hubert Hackl

Dr. Hubert Hackl

Institute of Bioinformatics, Biocenter, Medical University of Innsbruck, Innsbruck, Tyrol, Austria
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2009 in Bioinformatics
Verified
Journal Article
Open access
PDF file
GBGabriela Bindea
Gabriela Bindea
BMBernhard Mlecnik
Bernhard Mlecnik
Hubert HacklHubert Hackl
Hubert Hackl
PCPornpimol Charoentong
Pornpimol Charoentong
MTMarie Tosolini
Marie Tosolini
JGJerome Galon
Jerome Galon
Summary: We have developed ClueGO, an easy to use Cytoscape plug-in that strongly improves biological interpretation of large lists of genes. ClueGO integrates Gene Ontology (GO) terms as well as KEGG/BioCarta pathways and creates a functionally organized GO/pathway term network. It can analyze one or compare two lists of genes and comprehensively visualizes functionally grouped terms. A one-click update option allows ClueGO to automatically download the most recent GO/KEGG release at any time. ClueGO provides an intuitive representation of the analysis results and can be optionally used in conjunction with the GOlorize plug-in. Availability:http://www.ici.upmc.fr/cluego/cluegoDownload.shtml Contact:jerome.galon@crc.jussieu.fr Supplementary information: Supplementary data are available at Bioinformatics online.

1 January 2017 in Cell Reports
Verified
Journal Article
Open access
PCPornpimol Charoentong
Pornpimol Charoentong
FFFrancesca Finotello
Francesca Finotello
MAMihaela Angelova
Mihaela Angelova
CMClemens Mayer
Clemens Mayer
MEMirjana Efremova
Mirjana Efremova
ZTZlatko Trajanoski
Zlatko Trajanoski
The Cancer Genome Atlas revealed the genomic landscapes of human cancers. In parallel, immunotherapy is transforming the treatment of advanced cancers. Unfortunately, the majority of patients do not respond to immunotherapy, making the identification of predictive markers and the mechanisms of resistance an area of intense research. To increase our understanding of tumor-immune cell interactions, we characterized the intratumoral immune landscapes and the cancer antigenomes from 20 solid cancers and created The Cancer Immunome Atlas (https://tcia.at/). Cellular characterization of the immune infiltrates showed that tumor genotypes determine immunophenotypes and tumor escape mechanisms. Using machine learning, we identified determinants of tumor immunogenicity and developed a scoring scheme for the quantification termed immunophenoscore. The immunophenoscore was a superior predictor of response to anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) and anti-programmed cell death protein 1 (anti-PD-1) antibodies in two independent validation cohorts. Our findings and this resource may help inform cancer immunotherapy and facilitate the development of precision immuno-oncology.

24 May 2019 in Genome Medicine
Verified
Journal Article
Open access
PDF file
FFFrancesca Finotello
Francesca Finotello
CMClemens Mayer
Clemens Mayer
CPChristina Plattner
Christina Plattner
GLGerhard Laschober
Gerhard Laschober
DRDietmar Rieder
Dietmar Rieder
ZTZlatko Trajanoski
Zlatko Trajanoski
We introduce quanTIseq, a method to quantify the fractions of ten immune cell types from bulk RNA-sequencing data. quanTIseq was extensively validated in blood and tumor samples using simulated, flow cytometry, and immunohistochemistry data. quanTIseq analysis of 8000 tumor samples revealed that cytotoxic T cell infiltration is more strongly associated with the activation of the CXCR3/CXCL9 axis than with mutational load and that deconvolution-based cell scores have prognostic value in several solid cancers. Finally, we used quanTIseq to show how kinase inhibitors modulate the immune contexture and to reveal immune-cell types that underlie differential patients’ responses to checkpoint blockers. Availability: quanTIseq is available at http://icbi.at/quantiseq.

31 March 2015 in Genome Biology
Verified
Journal Article
Open access
PDF file
MAMihaela Angelova
Mihaela Angelova
PCPornpimol Charoentong
Pornpimol Charoentong
Hubert HacklHubert Hackl
Hubert Hackl
MFMaria L Fischer
Maria L Fischer
RSRene Snajder
Rene Snajder
ZTZlatko Trajanoski
Zlatko Trajanoski
Background: While large-scale cancer genomic projects are comprehensively characterizing the mutational spectrum of various cancers, so far little attention has been devoted to either define the antigenicity of these mutations or to characterize the immune responses they elicit. Here we present a strategy to characterize the immunophenotypes and the antigen-ome of human colorectal cancer. Results: We apply our strategy to a large colorectal cancer cohort (n = 598) and show that subpopulations of tumor-infiltrating lymphocytes are associated with distinct molecular phenotypes. The characterization of the antigenome shows that a large number of cancer-germline antigens are expressed in all patients. In contrast, neo-antigens are rarely shared between patients, indicating that cancer vaccination requires individualized strategy. Analysis of the genetic basis of the tumors reveals distinct tumor escape mechanisms for the patient subgroups. Hypermutated tumors are depleted of immunosuppressive cells and show upregulation of immunoinhibitory molecules. Non-hypermutated tumors are enriched with immunosuppressive cells, and the expression of immunoinhibitors and MHC molecules is downregulated. Reconstruction of the interaction network of tumor-infiltrating lymphocytes and immunomodulatory molecules followed by a validation with 11 independent cohorts (n = 1,945) identifies BCMA as a novel druggable target. Finally, linear regression modeling identifies major determinants of tumor immunogenicity, which include well-characterized modulators as well as a novel candidate, CCR8, which is then tested in an orthologous immunodeficient mouse model. Conclusions: The immunophenotypes of the tumors and the cancer antigenome remain widely unexplored, and our findings represent a step toward the development of personalized cancer immunotherapies.

1 April 2016 in Cell Host & Microbe
Verified
Journal Article
Closed access
AMAlexander R Moschen
Alexander R Moschen
RGRomana R. Gerner
Romana R. Gerner
JWJun Wang
Jun Wang
VKVictoria Klepsch
Victoria Klepsch
TATimon E. Adolph
Timon E. Adolph
HTHerbert Tilg
Herbert Tilg

4 July 2016 in Nature Reviews Genetics
Verified
Journal Article
Closed access
Hubert HacklHubert Hackl
Hubert Hackl
PCPornpimol Charoentong
Pornpimol Charoentong
FFFrancesca Finotello
Francesca Finotello
ZTZlatko Trajanoski
Zlatko Trajanoski